156 results
Page 5 of 8
8-K
EX-99.1
gjqyblssb5hk9t vk
28 Oct 19
Agios Presents Data from Single Agent Dose-Escalation Arm of Phase 1 Study ofAG-270, a MAT2A Inhibitor, in Patients withMTAP-Deleted Tumors
7:20am
8-K
EX-99.1
gpt0b33ny4m09u9vmtzi
30 Sep 19
Other Events
11:13am
8-K
EX-99.1
vd1g1c1 4e
4 Sep 19
Other Events
5:05pm
8-K
EX-99.1
988x7g8jv
1 Aug 19
Agios Reports Business Highlights and Second Quarter 2019 Financial Results
7:29am
8-K
EX-99.1
hex0nvbt
3 Jun 19
Other Events
4:02pm
8-K
EX-99.1
ekgwjgbaii
15 May 19
Achieved its Primary Endpoint in Previously Treated IDH1 Mutant Cholangiocarcinoma
4:13pm
8-K
EX-99.1
jrdty6mxoh 99eeqo3
2 May 19
Other Events
3:24pm
8-K
EX-99.1
yjarmoi21te557 dgbi
2 May 19
Agios Reports Business Highlights and First Quarter 2019 Financial Results
7:24am
8-K
EX-99.1
fnzf09za
14 Feb 19
Agios Reports Fourth Quarter and Full Year 2018 Financial Results
7:16am
8-K
EX-99.1
609qjt0
7 Jan 19
Agios Highlights Key 2019 Initiatives to Broaden Potential for Late-Stage Cancer and Rare Genetic Disease Programs to Build Long-Term Value
7:48am
8-K
EX-99.1
es3awmywhirvk3
3 Dec 18
Other Events
4:03pm
8-K
EX-99.2
25w0xuu l8
3 Dec 18
Other Events
4:03pm
8-K
EX-99.1
cne9 1m88vycla
16 Nov 18
Agios Presents Updated Data from Phase 1 Dose-Escalation Study ofAG-881 in Patients with IDH Mutant Positive Advanced Glioma
4:01pm
8-K
EX-99.1
fcfzh pi0oukx
1 Nov 18
Agios Reports Third Quarter 2018 Financial Results
7:45am